Martin P Lefkowitz Selected Research

paragon

1/2022	Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HF.
12/2021	Impact of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure With Preserved Ejection Fraction: Insights From PARAGON-HF.
1/2021	Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
1/2021	Serum potassium and outcomes in heart failure with preserved ejection fraction: a post-hoc analysis of the PARAGON-HF trial.
1/2021	Effects of Sacubitril/Valsartan on Serum Lipids in Heart Failure With Preserved Ejection Fraction.
11/2020	Serum uric acid, influence of sacubitril-valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON-HF.
1/2020	Angiotensin-Neprilysin Inhibition and Renal Outcomes in Heart Failure With Preserved Ejection Fraction.
10/2019	Health-Related Quality of Life in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.
1/2018	Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
1/2017	Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin P Lefkowitz Research Topics

Disease

41	Heart Failure 01/2022 - 09/2013
6	Cardiomyopathies (Cardiomyopathy) 01/2022 - 01/2018
5	Hypotension (Low Blood Pressure) 10/2019 - 09/2014
4	Heart Diseases (Heart Disease) 01/2022 - 01/2017
3	Chronic Kidney Failure (Chronic Renal Failure) 01/2022 - 01/2020
3	Angioedema 10/2019 - 09/2014
3	Hyperkalemia 10/2019 - 09/2014
3	Cardiovascular Diseases (Cardiovascular Disease) 01/2018 - 04/2010
2	Myocardial Infarction 01/2022 - 06/2017
2	Sudden Death 01/2022 - 06/2017
2	Chronic Obstructive Pulmonary Disease (COPD) 12/2021 - 01/2021
2	Diabetes Mellitus 01/2021 - 01/2016
2	Cough 01/2017 - 09/2014
2	Hypertension (High Blood Pressure) 11/2011 - 04/2010
1	Cardiac Arrhythmias (Arrythmia) 01/2022
1	Heart Arrest (Cardiac Arrest) 01/2022
1	Shock 01/2022
1	Paroxysmal Dyspnea (Paroxysmal Nocturnal Dyspnea) 10/2019
1	Edema (Dropsy) 10/2019
1	Dyspnea (Shortness of Breath) 10/2019
1	Chronic Renal Insufficiency 01/2018
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2018
1	Type 2 Diabetes Mellitus (MODY) 01/2018
1	Frailty 01/2018
1	Stroke (Strokes) 06/2017
1	Cognitive Dysfunction 01/2017
1	Dementia (Dementias) 01/2017
1	Disease Progression 01/2015
1	Systolic Heart Failure 09/2013
1	Essential Hypertension 11/2011

Drug/Important Bio-Agent (IBA)

32	sacubitril and valsartan sodium hydrate drug combinationIBA 01/2022 - 04/2010
22	Neprilysin (Neutral Endopeptidase)IBA 01/2022 - 09/2013
16	Enalapril FDA LinkGeneric 01/2022 - 09/2014
16	Angiotensin Receptors (Angiotensin II Receptor)IBA 12/2021 - 09/2013
10	paragonIBA 01/2022 - 01/2017
9	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2021 - 01/2015
8	Valsartan (Vals)FDA Link 01/2022 - 04/2010
6	AngiotensinsIBA 01/2022 - 09/2014
5	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022 - 01/2018
5	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 09/2013
4	Angiotensin Receptor AntagonistsIBA 12/2021 - 01/2018
4	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 01/2017 - 09/2013
3	DiureticsIBA 01/2021 - 01/2018
3	Biomarkers (Surrogate Marker)IBA 11/2020 - 10/2018
3	Natriuretic PeptidesIBA 10/2019 - 01/2017
3	Pharmaceutical PreparationsIBA 08/2017 - 04/2010
2	Uric Acid (Urate)IBA 11/2020 - 01/2018
2	sacubitrilIBA 10/2019 - 04/2010
1	CreatinineIBA 12/2021
1	PotassiumIBA 01/2021
1	LipidsIBA 01/2021
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021
1	Cardiovascular AgentsIBA 08/2017
1	Peptides (Polypeptides)IBA 01/2017
1	EnzymesIBA 01/2017
1	Hemoglobins (Hemoglobin)IBA 01/2016
1	Eplerenone (Inspra)FDA LinkGeneric 11/2015
1	AldosteroneIBA 11/2011
1	OsilodrostatIBA 11/2011
1	Cytochrome P-450 CYP11B2 (CYP11B2)IBA 11/2011

Therapy/Procedure

11	Therapeutics 01/2021 - 04/2014
1	Defibrillators (Defibrillator) 01/2022
1	Cardiac Resynchronization Therapy 01/2022
1	Implantable Defibrillators (Implantable Cardioverter-Defibrillator) 01/2022
1	Patient Readmission 01/2020
1	Drug Tapering 01/2017
1	Heart Transplantation (Grafting, Heart) 01/2015
1	Critical Care (Surgical Intensive Care) 01/2015